NAD+ injection dosing on TikTok: what the science actually says

A recent TikTok video by Christa Miranda, an Arizona realtor, documents her experience with NAD+ injections. In the clip, she explains that during week one her body was 'just introduced' to the treatment, and that in the following week she increased her dose from 5 ml to 25 ml, calling this her 'official first dose.' The video is tagged with #antiaging, #NAD, #nadinjections, and #stemcelltherapy, and it appears to be part of a sponsored or affiliate partnership with a health clinic.

What the clip is claiming

The core claim is that a 5 ml to 25 ml increase in NAD+ injection volume represents a normal or recommended progression, and that this constitutes a 'first dose' after a week of acclimation. The video implies that this dosing schedule is safe and effective for anti-aging and pain management, and it subtly aligns NAD+ with stem cell therapy—a connection that is not supported by current research.

What the research neighborhood actually covers

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy production and DNA repair. Research on NAD+ precursors (like nicotinamide riboside or NMN) has explored potential benefits for metabolic health, mitochondrial function, and age-related decline. However, clinical studies on injectable NAD+ are sparse, and most evidence comes from animal models or small human trials using oral supplements, not injections.

Dosing in research is typically reported in milligrams (mg) per kilogram of body weight, not milliliters (ml). A milliliter is a volume measure, and the concentration of NAD+ in a solution can vary widely. Without knowing the concentration (e.g., mg/ml), stating a dose in ml is meaningless. The jump from 5 ml to 25 ml—a fivefold increase—is not supported by any published protocol we could identify.

Limits, missing context, and what a 15-second clip cannot show

A short video cannot convey the nuances of dosing, the importance of medical supervision, or the potential side effects. NAD+ injections can cause flushing, nausea, and injection-site reactions. Rapid dose escalation may increase these risks. Moreover, the clip does not mention the concentration of the solution, the specific product used, or whether a healthcare provider approved the change. The phrase 'official first dose' is ambiguous—does it mean the first therapeutic dose after a loading phase, or the first dose of a new protocol?

Additionally, the hashtag #stemcelltherapy is misleading. NAD+ is not a stem cell therapy; it does not introduce stem cells or directly stimulate stem cell production. While NAD+ may influence cellular repair pathways, equating it with stem cell therapy is not scientifically accurate.

How this maps to named research compounds

In the context of our catalog, the compound most relevant to this clip is NAD+ itself. Our NAD+ is a research-use peptide (RUO) intended for laboratory investigations only. It is not approved for human use, and no dosing recommendations can be made. Other catalog compounds, such as BPC-157 or TB-500, are sometimes discussed in anti-aging or pain management contexts, but they are not mentioned in this clip, so we will not speculate on their relevance.

Research-use caveat

All peptides and compounds in our catalog are sold for research purposes only. They are not intended for diagnostic, therapeutic, or clinical use. Researchers must adhere to institutional guidelines and ethical standards. The information in this article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for any health-related decisions.